Hibernaid is a privately held company developing unique drugs for important acute medical indications in high-risk critical care patient populations.

The Company's lead development compound is HBN-1, a unique intravenous combination drug that pharmaceutically induces clinically-relevant regulated hypothermia or temperature management (deliberate reduction of core body temperature) to prevent neurological, functional and organ damage and significantly increase the probability of survival in a broad range of acute care medical conditions.

HBN-1 is initially being developed for use in resuscitated post-cardiac arrest patients but the technology will also be developed for the treatment of stroke, traumatic brain injury, spinal cord injury and other acute critical care indications.